Fibromyalgia and Gaucher's disease

QJM: An International Journal of Medicine

Volumn 99, Issue 2, 2006, Pages 103-107

  Brautbar, A ^a   Elstein, D ^a   Pines, B ^a   Krienen, N ^a   Hemmer, J ^a   Buskila, D ^b   Zimran, A ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE DISEASE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; ENZYME THERAPY; FEMALE; FIBROMYALGIA; GAUCHER DISEASE; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 32244434558     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci147     Document Type: Article

References (25)

1. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Valle D, Beudet A, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Diseases. New York, McGraw-Hill, 2001: III:3635-68.
2. Grabowski GA, Horowitz M. Gaucher's disease: Molecular, genetic and enzymological aspects. Clin Haematol 1997; 10:635-6.
3. Azuri J, Elstein D, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A. Asymptomatic Gaucher disease implications for large-scale screening. Genet Test 1998; 2:297-9.
4. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324:1464-70.
5. Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 1999; 8:263-8.
6. Dayan B, Elstein D, Zimran A, Nesher G. Decreased salivary output in patients with Gaucher disease. Q J Med 2003; 96:53-6.
7. vom Dahl S, Harzer K, Rolfs A, Albrecht B, Niederau C, Vogt C, et al. Hepatosplenomegalic lipidosis: What unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chito-triosidase activity and a homozygous lysosomal acid lipase-1 exon 8 splice junction mutation. J Hepatol 1999; 31:741-6.
8. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292:2388-95.
9. Buskila D, Neumann L, Sibirski D, Shvartzman P. Awareness of diagnostic and clinical features of fibromyalgia among family physicians. Fam Pract 1997; 14:238-41.
10. Gallagher AM, Thomas JM, Hamilton WT, White PD. Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to 2001. J R Soc Med 2004; 97:571-5.
11. Gur A, Cevik R, Sarac AJ, Colpan L, Em S. Hypothalamic-pituitary-gonadal axis and cortisol in young women with primary fibromyalgia: The potential roles of depression, fatigue, and sleep disturbance in the occurrence of hypocortisolism. Ann Rheum Dis 2004; 63:1504-6.
12. Ribeiro LS, Proietti FA. Interrelations between fibromyalgia, thyroid autoantibodies, and depression. J Rheumatol 2004; 31:2036-40.
13. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. Curr Pain Headache Rep 2004; 8:385-9.
14. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50:2974-84.
15. Meenan RF, Gertman PM, Mason JM. Measuring health status in arthritis: The arthritis impact measurement scales. Arthritis Rheum 1980; 23:146-52.
16. Mishkin A, Cohen-Hadad G, Lang M, Kofler E, Vardi Y, Schrira S, et al. Demographic, clinical and treatment characteristics among Meuhedet sick fund mental health referrals. Isr J Psychiatry Relat Sci 2003; 40:297-303.
17. Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E. Prediction of severity of Gauchers disease by identification of mutations at DNA level. Lancet 1989; 2:349-52.
18. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33:160-72.
19. Maquet D, Croisier JL, Demoulin C, Crielaard JM. Pressure pain thresholds of tender point sites in patients with fibromyalgia and in healthy controls. Eur J Pain 2004; 8:111-17.
20. Hauser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2004; 2:157-63.
21. Spath M, Stratz T, Neeck G, Kotter I, Hammel B, Amberger CC, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004; 33:267-70.
22. Schwarz MJ, Offenbaecher M, Neumeister A, Ackenheil M. Experimental evaluation of an altered tryptophan metabolism in fibromyalgia. Adv Exp Med Biol 2003; 527:265-75.
23. Harrison BJ, Olver JS, Norman TR, Nathan PJ. Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Hum Psychopharmacol 2002; 17:293-7.
24. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: Increased release of interleukin-6 and interleukin-10. Q J Med 1997; 90:19-25.
25. Altarescu G, Phillips M, Foldes AJ, Elstein D, Zimran A, Mates M. The interleukin-6 promoter polymorphism in Gaucher disease: A new modifier gene? Q J Med 2003; 96:575-8.